arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Harmony Biosciences Holdings, Inc.

HRMY
$38.41 ▼ -0.34 (-0.89%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
8 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
84
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Harmony Biosciences Holdings, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $2.2B
Dividend Yield
Revenue Growth 21.5%
Op. Margin 24.0%
ROIC 14.9%
FCF / Share $6.05
Trailing P/E 13.9x
Price / Book 2.6x
FCF Yield 15.8%
Debt / Equity 0.19
info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$868.45M
↑ +21.5%
Net Income Profit after all expenses
$158.69M
↑ +9.1%
Operating Margin Operating profit as % of sales
24.0%
↓ -10.1% 80th
FCF / Share Free cash flow per share
$6.05
↑ +57.4%
Long-Term Debt Long-term obligations
$163.66M
↓ -8.7%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
85
Returns
84
Financial Health
79
Cash Quality
88

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 29 quarters